Owing to the dual nature of ROS in cancer, NRF2 and its antagonist, Kelch-like ECH-associated protein 1 (KEAP1), have become subjects of debate regarding their precise roles in either preventing or, conversely, promoting tumor progression [24]. This evidence concerns the gene KEAP1 and neoplasm.